June 26, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
- /
- /
Click to Subscribe for the MS Beacon eNewsletter, resources and MS education …
